CRYO Cryo-Save

 

TIDMCRYO 
 
RNS Number : 8773I 
Cryo-Save Group NV 
19 March 2010 
 

19 March 2010 
 
Cryo-Save Group N.V. 
 
Non-Executive Director appointment 
 
Cryo-Save Group N.V. (AIM/Euronext: CRYO, "Cryo-Save" or "the Group"), Europe's 
leading stem cell bank, announces that Dr. Ronald H.W. Lorijn will be appointed 
as Non-Executive Director with effect from Cryo-Save's AGM, which is expected to 
be on 19 May 2010, subject to shareholder approval. 
 
As Chief Executive of AMT NV (Amsterdam), Dr. Lorijn (MD, PhD, MBA) developed 
AMT from a small, one-product operation into a leading gene therapy company 
listed on the NYSE Euronext. Dr. Lorijn retired from AMT in February 2009. 
Previous to AMT, Dr. Lorijn was a member of Amgen, a leading human therapeutics 
company, where he was part of Amgen Europe's executive management team and 
responsible for its Clinical Operations, Business Development & Governmental 
Affairs. 
 
Before joining Amgen he was Chief Medical Officer and Senior Director of 
Clinical Operations & Medical Affairs, Europe at Centocor after having been 
employed by the pharmaceutical division of AKZO (Organon), as its head of 
worldwide Medical Services and Product Surveillance. 
 
Dr. Lorijn graduated from the Radboud University Nijmegen, completed a Ph.D. and 
was a certified obstetrician/gynaecologist before joining the biotech industry. 
 
Marc Waeterschoot, Chief Executive, commented: 
 
"I am very pleased that Ronald has accepted the invitation to join our Board. 
With his wide experience in the life-sciences business with internationally 
operating and fast growing companies, he will certainly contribute to the 
further successful execution of our strategy." 
 
Further information required to be disclosed in respect of the above appointment 
pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies, is as 
follows: Dr. Ronald Hans Wilmar Lorijn, age 58, is a director of LxpR (a private 
company) and until February 2009 was Chief Executive of AMT N.V. Dr. Lorijn does 
not hold shares in Cryo-Save. 
 
 
+-------------------------------+----------------------------+ 
| For further details:          |                            | 
+-------------------------------+----------------------------+ 
|                               |                            | 
+-------------------------------+----------------------------+ 
| Cryo-Save Group               |       + 31 (0) 575 548 998 | 
+-------------------------------+----------------------------+ 
| Marc Waeterschoot, Chief      |                            | 
| Executive                     |                            | 
| Arnoud van Tulder, Chief      |                            | 
| Financial Officer             |                            | 
+-------------------------------+----------------------------+ 
|                               |                            | 
+-------------------------------+----------------------------+ 
| Daniel Stewart & Company plc  |      + 44 (0) 20 7776 6550 | 
+-------------------------------+----------------------------+ 
| Simon Leathers / Emma Earl    |                            | 
+-------------------------------+----------------------------+ 
|                               |                            | 
+-------------------------------+----------------------------+ 
| College Hill                  |     + 44 (0) 20 7457 2020  | 
+-------------------------------+----------------------------+ 
| Adrian Duffield/Rozi Morris   |                            | 
+-------------------------------+----------------------------+ 
 
 
 About Cryo-Save 
With more than 120,000 samples saved, Cryo-Save is the leading stem cell bank in 
Europe and one of the fastest growing in the world.  Driven by its international 
business strategy, Cryo-Save is now represented in 38 countries on three 
continents and has state-of-the-art processing facilities in Belgium, Germany, 
Dubai, India and France (under construction). 
Cryo-Save sets the highest quality standards in stem cell storage, as it aims to 
make an important contribution to conquer possible life-threatening diseases in 
the future. As a service to the public, Cryo-Save offers a Cost-free Family 
Donation Programme, free of charge, to families wishing to store their newborn's 
umbilical cord blood stem cells for a family member diagnosed with a 
life-threatening disease treatable by stem cells. The company is committed to 
further improve stem cell cryopreservation techniques, by participating in 
European Commission funded projects, in Universities and Hospitals. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOAZKLFFBXFBBBD 
 

Cryo-Save (LSE:CRYO)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Cryo-Save (LSE:CRYO)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025